GLUT1: A novel tool reflecting proliferative activity of lung neuroendocrine tumors?

Benzerdjeb, Nazim; Berna, Pascal; Sevestre, Henri

doi:10.1111/pin.12486

Cited by 12 publications

(9 citation statements)

References 27 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We confirm here that CA9 and GLUT1 plasma membrane expression is associated with a high tumor grade in NEN. This is in accordance with previous data published regarding lung NEN [6,31]. We also observed that tumors with low pVHL expression had a significantly higher SUV max .…”

Section: Discussionsupporting

confidence: 83%

18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation

Bucau¹,

Laurent-Bellue²,

Poté³

et al. 2017

Neuroendocrinology

View full text Add to dashboard Cite

Background:¹⁸F-FDG-PET scan positivity correlates with poor prognosis in neuroendocrine neoplasms (NEN). Glucose transporter 1 (GLUT1) and carbonic anhydrase 9 (CA9) are markers of aggressiveness in tumors. Together with von Hippel-Lindau protein (pVHL), they are involved in tumor cell metabolism via the hypoxia-inducible factor signaling pathway. The aim of this study was to compare, in a series of well-differentiated neuroendocrine tumors (NET), the ¹⁸F-FDG uptake and expression of the proliferation markers Ki-67, GLUT1, CA9, and pVHL. Patients and Methods: This retrospective study included 27 patients with well-differentiated NET. ¹⁸F-FDG-PET images were evaluated by the maximum standardized uptake value (SUV_max). GLUT1, CA9, and pVHL were analyzed by immunohistochemistry. Results: The NET were of pancreatic (n = 19), midgut (n = 4), duodenal (n = 1), esophageal (n = 1), rectal (n = 1), and pulmonary (n = 1) origin. Eight, 11, and 8 tumors were grade 1, 2, and 3, respectively. The mean/median Ki-67 index was 15/10% (1-60). The mean/median SUV_max was 6.2/5.2 (1.4-18.7). SUV_max correlated with greater tumor size (p = 0.03), higher expression of Ki-67 (p = 0.04), and lower expression of pVHL (p = 0.008). In the group of 16 NET with a low proliferative index (Ki-67 index <10%), 5/6 (83%) of the tumors with a high SUV_max had decreased pVHL expression (p = 0.0013). Conclusion: This study confirms that ¹⁸F-FDG-PET uptake correlates with both tumor size and proliferation in well-differentiated NET, and it highlights a subset of low-grade but ¹⁸F-FDG-PET-positive NET related to sporadic inactivation of the VHL pathway.

show abstract

Section: Discussionsupporting

confidence: 83%

18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation

Bucau¹,

Laurent-Bellue²,

Poté³

et al. 2017

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Other authors considered that LNETs represent 20% of the total number of lung cancer cases (10). In addition to the single pulmonary localizations there have been cases described of two or more carcinoid tumors or tumorlets of the lung, gastrointestinal tract and pancreas.…”

Section: Lung Neuroendocrine Tumors: a Systematic Literature Review (Review)mentioning

confidence: 99%

Lung neuroendocrine tumors: A systematic literature review (Review)

et al. 2021

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) can have multiple localizations in the human body however, most often, it appears in the in thorax at tracheobronchial tree and the thymus. NETs are a group of tumors with heterogenous malignancy that evolve from neuroendocrine cells, with the lung being the second target organ after the gastrointestinal tract. These rare tumors are usually asymptomatic and non-functional with little information regarding incidence in the specialty literature. The main purpose of this review, was the analysis of the available literature in all aspects while mainly focusing on molecular diagnosis data and secondly, by using this molecular landscape to establish a differentiation of lung neuroendocrine tumors (LNETs). By analyzing the literature, new data were revealed regarding histological evaluation, genetic aberrations, prognosis depending on the type of LNET and therapeutic options that derive from these. Efficient management of these tumors is essential in the handling of symptoms and increase in life expectancy, especially in patients with functional tumors. Histological differentiation of LNETs is important in establishing proper therapeutic options and prognosis. Combined types of LNETs remain a controversial topic of discussion regarding diagnosis and treatment, a topic on which further studies are required in order to improve diagnosis in this group of tumors with heterogenous malignancy. Contents1. Introduction 2. Materials and methods 3. Epidemiology 4. Classification 5. Precursor lesions 6. Clinical features 7. Tumor staging 8. Biological landscape of lung neuroendocrine tumors (LNETs) 9. Radiological diagnosis 10. Surgical treatment 11. Advanced LNETs therapy 12. Conclusions

show abstract

“…FDG uptake is correlated with neuroendocrine tumor aggressiveness, and GLUT-1 expression has a significant relation to FDG accumulation [63]. The sensitivity of PET/CT can differ according to the grade of differentiation, which is relatively low in G1 or G2 neoplasms and higher in poorly differentiated neuroendocrine carcinomas.…”

Section: Primary and Metastatic Neuroendocrine Tumorsmentioning

confidence: 99%

FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background

et al. 2020

View full text Add to dashboard Cite

The usefulness of whole-body 18-fluoro-2-deoxyglucose (FDG)-fluorodeoxyglucose positron emission (PET)/computed tomography (CT) is established for assessment of disease staging, detection of early disease recurrence, therapeutic evaluation, and predicting prognosis in various malignancies; and for evaluating the spread of inflammation. However, the role of FDG-PET/CT for the liver is limited because CT and magnetic resonance imaging (MRI) can provide an accurate diagnosis of most tumors. In addition, in other potentially useful roles there are several pitfalls in the interpretation of FDG uptake in PET/CT imaging. Accurate evaluation demands knowledge of the FDG uptake of each lesion, including potential negative and positive uptakes, and requires an understanding of the underlying background of the molecular mechanisms. The degree of FDG uptake is dependent on cellular metabolic rate and the expression of glucose transporter, hexokinase, and glucose-6-phosphatase, which in turn are closely affected by biological characteristics such as pathological category (e.g., adenocarcinoma, squamous cell carcinoma, small cell cancer, transitional cell cancer, neuroendocrine tumor, sarcoma, lymphoma), tumor differentiation, histological behavior (e.g., solid, cystic, mucinous), and intratumoral alterations (e.g., necrosis, degeneration, hemorrhage). Correlation with the CT and MRI findings, which also precisely depict the pathological findings, is important to avoid misdiagnosis.

show abstract

GLUT1: A novel tool reflecting proliferative activity of lung neuroendocrine tumors?

Cited by 12 publications

References 27 publications

18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation

18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation

Lung neuroendocrine tumors: A systematic literature review (Review)

FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background

Contact Info

Product

Resources

About